Troluce Capital Advisors LLC Dyne Therapeutics, Inc. Call Options Transaction History
Troluce Capital Advisors LLC
- $826 Million
- Q2 2024
Call Options
1 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$261 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$256 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$241 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$208 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$197 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.69B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...